INFLUENCE OF HIGH BODY MASS INDEX ON SENSITIVITY TO NEOADJUVANT CHEMOTHERAPY OF TUMOR IN BREAST CANCER
Keywords:
breast cancer, body mass index, neoadjuvant chemotherapy, premenopausal period, resistantAbstract
To evaluate the effect of body mass index on tumor response to chemotherapy in breast cancer.
Background. Obesity is not only one of the risk factors leading to breast cancer but how obesity accompanies cancer is crucial for evaluating the effects of the disease. This article examines the role of obesity in the occurrence and course of breast cancer in women and their involvement in tumor development and progression.
Material and methods. The retrospective study was conducted on 24 patients with early-stage breast cancer women who accepted neoadjuvant chemotherapy in the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology. The patients were divided into two groups depending on the BMI of women: the first group included BMI≤30 (control group), and the second group consisted of BMI≥30 women.
Results. In patients with a high body mass index, the indicators indicate that, regardless of the number of NCHT courses due to obesity, tumor sensitivity is lower than in patients with an average body mass index (p<0.01).
Conclusion. A decrease in the body mass index in patients with breast cancer leads to an improvement in the disease outcomes and a reduction in the resistantce of the tumor to chemotherapy.
References
Renée T. Fortner, Verena Katzke, Tilman Kühn and Rudolf Kaaks. Obesity and Breast Cancer. Recent Resultsin Cancer Research 208.
Nicoletta Biglia, Elisa Peano, Paola Sgandurra, Giulia Moggio, Silvia Pecchio, Furio Maggiorotto &Piero Sismondi. Body mass index (BMI) and breast cancer: impact on tumorhistopatologic features, cancer subtypes and recurrence rate in preand postmenopausal women. Gynecological Endocrinology, 2013; 29(3): 263–267.
World Health Organization (WHO) (2008). WHO, global database on body mass index, BMI classification; 30-4-2008.
Ana Maria Gonzalez-Angulo , Flavia Morales-Vasquez, Gabriel N Hortobagyi. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22
Kuerer HM, Newman LA, Buzdar AU et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer Journal From Scientific American 1998; 4:230–236.
Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672–2685.
Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165–4174.
Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3(Suppl 2):S69–S74.
L.T.Alimkhodjaeva and others. The effect of body mass index on the clinical and morphological characteristics of breast cancer in women with metabolic syndrome. American journal of medicine and medical sciences. 2023,13(8):1118-1122.
Manuel Picon-Ruiz, PhD, Cynthia Morata-Tarifa, PhD, Janeiro J. Valle-Goffin, MD, Eitan R. Friedman, MD, and Joyce M. Slingerland Obesity and Adverse Breast Cancer Risk and Outcome: Mechanistic Insights and Strategies/ CA CANCER J CLIN 2017;00:00–00
